Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Viemed Healthcare (VMD) Shares Outstanding (Weighted Average) (2018 - 2025)

Viemed Healthcare (VMD) has disclosed Shares Outstanding (Weighted Average) for 6 consecutive years, with $38.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) changed 0.36% year-over-year to $38.9 million, compared with a TTM value of $38.9 million through Dec 2025, changed 0.36%, and an annual FY2025 reading of $38.9 million, changed 0.36% over the prior year.
  • Shares Outstanding (Weighted Average) was $38.9 million for Q4 2025 at Viemed Healthcare, up from $38.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $39.6 million in Q1 2022 and bottomed at $38.2 million in Q1 2023.
  • Average Shares Outstanding (Weighted Average) over 5 years is $38.9 million, with a median of $38.8 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Weighted Average) rose 2.89% in 2021, then decreased 3.7% in 2023.
  • Year by year, Shares Outstanding (Weighted Average) stood at $39.5 million in 2021, then fell by 2.12% to $38.7 million in 2022, then dropped by 0.78% to $38.4 million in 2023, then grew by 1.05% to $38.8 million in 2024, then rose by 0.36% to $38.9 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for VMD at $38.9 million in Q4 2025, $38.6 million in Q3 2025, and $39.5 million in Q2 2025.